Central Bank leaves refinancing rate unchanged taking into account high uncertainty in US economic policy

YEREVAN, May 6. /ARКА/. The Central Bank of Armenia decided today to leave the refinancing rate unchanged at 6.75% taking into account a set of factors such as  the continued high uncertainty surrounding the US economic policy, declining confidence in the global economy, growth slowdown and  a possible  weakening demand in Armenia, the head of the regulator Martin Galstyan said at a press conference on Tuesday.

According to him, these factors underlie Scenario B – one of the two scenarios that the Central Bank relies on when determining the refinancing rate.

According to Galstyan, Scenario A is based on uncertainties, including factors related to geopolitics and the fiscal policy.

“These uncertainties  require higher interest rates than market expectations to ensure price stability,” he said, adding that the regulator sees the need to manage the significant macroeconomic implications that follow from this scenario. -0-

spot_img

POPULAR

Armenia set to enhance development of its capital market, targeting large issuers and new investors

YEREVAN, August 20. /ARKA/. The Armenian government prioritizes diversifying funding sources and advancing the capital market to foster sustainable and productive economic growth.

“AGROVISION” CJSC’s bonds were listed on Armenia Stock Exchange

YEREVAN, August 17. /ARKA/.  Today, “AGROVISION” CJSC, a company operating in the agro-industrial sector, became a listed company on the Armenia Stock Exchange (AMX).

US dollar, euro, and ruble drop against Armenian dram

YEREVAN, August 18. /ARKA/. The average market exchange rate for the US dollar against the Armenian dram on the Armenian foreign exchange market as of August 18, 2026, fell by 0.25 points to 365.25 drams compared to August 17.

An unusual $2.2 million banking scam uncovered in Armenia

YEREVAN, August 14. /ARКА/. A man suspected of embezzling 802.5 million drams from a bank and money laundering has been arrested in Armenia. The preliminary investigation has been completed, the press service of the RA Investigative Committee reported.

Shares of Noubar Afeyan’s Moderna soared 124% on news of a successful cancer vaccine trial

YEREVAN, August 20. /ARKA/. Shares of the biotech company Moderna soared 123.6% at the start of trading in the US on August 19, reaching a peak of $140.77, according to trading data. Shares of the pharmaceutical company Merck also rose 11.6% to $150.85, according to Forbes.ru.

LATEST NEWS

spot_imgspot_imgspot_img